中药调节糖尿病心肌病患者肠道菌群失调机制研究进展

doi:10.7501/j.issn.0253-2670.2024.08.028

温馨提示：建议您使用Chrome80、火狐74+、IE9+浏览器，当您的浏览器版本过低，可能会影响部分功能正常使用。

主办：天津药物研究院中国药学会

微信公众号

网站二维码

2025年6月13日 11:12 星期五

首页 > 过刊浏览>2024年第55卷第8期 >2024,55(8):2792-2799. DOI:10.7501/j.issn.0253-2670.2024.08.028

中药调节糖尿病心肌病患者肠道菌群失调机制研究进展

程安然
程安然
山东中医药大学第一临床医学院, 山东济南 250014
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
崔德芝
崔德芝
山东中医药大学附属医院, 山东济南 250014
通讯作者.
Email: dezhi1965@126.com
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

Research progress on mechanism of traditional Chinese medicine regulating intestinal flora imbalance in patients with diabetic cardiomyopathy

CHENG Anran
CHENG Anran
First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250014, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
CUI Dezhi
CUI Dezhi
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China
Contact Author.
Email: dezhi1965@126.com
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

发布日期：2024-04-19

摘要
图/表
访问统计
PDF预览
参考文献
相似文献
引证文献
附件

[关键词]

肠道菌群 ; 糖尿病心肌病 ; 代谢产物 ; 心肌细胞 ; 能量代谢障碍 ; 炎症反应 ; 小檗碱 ; 白藜芦醇 ; 黄芪多糖

[摘要]

糖尿病心肌病(diabetic cardiomyopathy,DCM)作为糖尿病患者最常见的并发症之一,是全球范围内造成糖尿病患者死亡的主要原因,其发病机制复杂且死亡率逐年上升。大量研究表明,肠道菌群及其代谢产物与DCM的发生发展密切相关,有望成为治疗DCM的潜在靶点。基于中药多成分、多靶点、多通路调控疾病的特点,目前已证实其在改善DCM患者预后及生存质量方面显示出独特优势。故通过总结以肠道菌群为靶点的中药治疗DCM的机制与优势,为DCM的基础研究、临床应用及新药研发提供新思路。

[Key word]

Intestinal flora ; diabetic cardiomyopathy ; metabolite ; cardiomyocytes ; energy metabolism disorder ; inflammatory response ; berberine ; resveratrol ; astragalus polysaccharides

[Abstract]

Diabetic cardiomyopathy (DCM), as one of the most common complications of diabetes, is the leading cause of death in diabetic patients worldwide. Its pathogenesis is complex and the mortality rate is increasing year by year. A large number of studies have shown that intestinal flora and its metabolites are closely related to the occurrence and development of DCM, and intestinal flora is expected to become a potential target for treatment of DCM. Based on the characteristics of multi-component, multi-target and multi-pathway regulation of traditional Chinese medicine, it has been confirmed that it has unique advantages in improving the prognosis and quality of life of DCM patients. Therefore, this article summarizes the mechanism and advantages of traditional Chinese medicine targeting intestinal flora in treatment of DCM, in order to provide new ideas for the basic research, clinical application and new drug development of DCM.

[中图分类号]

[基金项目]

山东省中医药科技项目（2020M011）

引用本文 / Get Citation

程安然,崔德芝.中药调节糖尿病心肌病患者肠道菌群失调机制研究进展[J].中草药,2024,55(8):2792-2799

分享 / Share

文章指标 / Article Metrics

点击次数: 359

下载次数: 1122

Html阅读次数: 0

引用次数: 0

历史 / History

收稿日期: 2023-10-05

在线发布日期: 2024-04-19

出版日期: 2024-04-28

[1] Rubler S, Dlugash J, Yuceoglu Y Z, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis[J]. Am J Cardiol, 1972, 30(6):595-602.

[2] Wang M R, Li Y S, Li S, et al. Endothelial dysfunction and diabetic cardiomyopathy[J]. Front Endocrinol, 2022, 13:851941.

[3] Kitai T, Tang W H W. Gut microbiota in cardiovascular disease and heart failure[J]. Clin Sci, 2018, 132(1):85-91.

[4] Bugger H, Abel E D. Molecular mechanisms of diabetic cardiomyopathy[J]. Diabetologia, 2014, 57(4):660-671.

[5] Avagimyan A, Popov S, Shalnova S. The pathophysiological basis of diabetic cardiomyopathy development[J]. Curr Probl Cardiol, 2022, 47(9):101156.

[6] Qin J J, Li R Q, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature, 2010, 464(7285):59-65.

[7] Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism[J]. Nature, 2012, 489(7415):242-249.

[8] Zhou B L, Yuan Y T, Zhang S S, et al. Intestinal flora and disease mutually shape the regional immune system in the intestinal tract[J]. Front Immunol, 2020, 11:575.

[9] Ahmad A, Yang W W, Chen G F, et al. Analysis of gut microbiota of obese individuals with type 2 diabetes and healthy individuals[J]. PLoS One, 2019, 14(12):e0226372.

[10] Yang T, Santisteban M M, Rodriguez V, et al. Gut dysbiosis is linked to hypertension[J]. Hypertension, 2015, 65(6):1331-1340.

[11] 陈茜,薛勇,宋晓峰,等.糖尿病及糖尿病心血管并发症患者肠道菌群的特征[J].微生物学报, 2019, 59(9):1660-1673.

[12] Chong C R, Clarke K, Levelt E. Metabolic remodelling in diabetic cardiomyopathy[J]. Cardiovasc Res, 2017, 113(4):422-430.

[13] Zhang Y F, Gu Y Y, Ren H H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)[J]. Nat Commun, 2020, 11:5015.

[14] 高文静.黄芪囊泡样纳米颗粒的药效学初步研究[D].北京:中国中医科学院, 2022.

[15] Tawulie D, Jin L L, Shang X, et al. Jiang-Tang-San-Huang pill alleviates type 2 diabetes mellitus through modulating the gut microbiota and bile acids metabolism[J]. Phytomedicine, 2023, 113:154733.

[16] Cao Y, Yao G W, Sheng Y Y, et al. JinQi Jiangtang Tablet regulates gut microbiota and improve insulin sensitivity in type 2 diabetes mice[J]. J Diabetes Res, 2019, 2019:1872134.

[17] Sun S S, Wang K, Ma K, et al. An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia, hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota[J]. Chin J Nat Med, 2019, 17(1):3-14.

[18] Razmpoosh E, Javadi A, Ejtahed H S, et al. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes:A randomized placebo controlled trial[J]. Diabetes Metab Syndr, 2019, 13(1):175-182.

[19] 张成英,杨翠,陈少军.归脾汤加减治疗慢性心力衰竭的疗效及对肠道菌群的影响[J].中西医结合心脑血管病杂志, 2023, 21(9):1664-1668.

[20] Fan X J, Zhang Y Y, Song Y, et al. Compound Danshen Dripping Pills moderate intestinal flora and the TLR4/MyD88/NF-κB signaling pathway in alleviating cognitive dysfunction in type 2 diabetic KK-Ay mice[J]. Phytomedicine, 2023, 111:154656.

[21] Qi Y, Liu W Z, Yan X F, et al. Tongxinluo may alleviate inflammation and improve the stability of atherosclerotic plaques by changing the intestinal flora[J]. Front Pharmacol, 2022, 13:805266.

[22] 李琳,曾逸笛,叶家豪,等.基于益气养阴法探讨参麦注射液调控肠道菌群-TMAO-炎症轴防治慢性心力衰竭的思路与策略[J].湖南中医药大学学报, 2023, 43(7):1258-1262.

[23] 辛来运.健脾益心方治疗心衰心脾两虚证的临床疗效评价及对心衰大鼠肠道菌群和炎症反应的影响[D].济南:山东中医药大学, 2022.

[24] Huang Y L, Xiang Q, Zou J J, et al. Zuogui Jiangtang Shuxin Formula ameliorates diabetic cardiomyopathy mice via modulating gut-heart axis[J]. Front Endocrinol, 2023, 14:1106812.

[25] Song X, Liu L, Peng S W, et al. Resveratrol regulates intestinal barrier function in cyclophosphamide-induced immunosuppressed mice[J]. J Sci Food Agric, 2022, 102(3):1205-1215.

[26] Gu J F, Su S L, Guo J M, et al. The aerial parts of Salvia miltiorrhiza Bge. strengthen intestinal barrier and modulate gut microbiota imbalance in streptozocin-induced diabetic mice[J]. J Funct Foods, 2017, 36:362-374.

[27] Wang Y, Liu H Y, Zheng M Y, et al. Berberine slows the progression of prediabetes to diabetes in zucker diabetic fatty rats by enhancing intestinal secretion of glucagon-like peptide-2 and improving the gut microbiota[J]. Front Endocrinol, 2021, 12:609134.

[28] Zhou G F, Jiang Y H, Ma D F, et al. Xiao-qing-long Tang prevents cardiomyocyte hypertrophy, fibrosis, and the development of heart failure with preserved ejection faction in rats by modulating the composition of the gut microbiota[J]. Biomed Res Int, 2019, 2019:9637479.

[29] 卢永康,陈窕圆,庄贤勉,等.基于调节肠道菌群失衡的四君子汤干预心力衰竭大鼠机制研究[J].中国中医药信息杂志, 2021, 28(4):81-87.

[30] 汪舒云,谢曼丽,孙可向,等.参苓白术散对大肠癌移植瘤模型小鼠化学疗法后肠道黏膜屏障的影响[J].上海中医药杂志, 2023, 57(4):57-64.

[31] Jones R M, Neish A S. Redox signaling mediated by the gut microbiota[J]. Free Radic Biol Med, 2017, 105:41-47.

[32] Li X W, Chen H P, He Y Y, et al. Effects of rich-polyphenols extract of Dendrobium loddigesii on anti-diabetic, anti-inflammatory, anti-oxidant, and gut microbiota modulation in db/db mice[J]. Molecules, 2018, 23(12):3245.

[33] Du Z Y, Wang J L, Lu Y Y, et al. The cardiac protection of Baoyuan Decoction via gut-heart axis metabolic pathway[J]. Phytomedicine, 2020, 79:153322.

[34] Zhang W J, Su W W, Li P B, et al. Naoxintong capsule inhibits the development of cardiovascular pathological changes in Bama minipig through improving gut microbiota[J]. Front Pharmacol, 2019, 10:1128.

[35] Feng J F, Tang Y N, Ji H, et al. Biotransformation of Dioscorea nipponica by rat intestinal microflora and cardioprotective effects of diosgenin[J]. Oxid Med Cell Longev, 2017, 2017:4176518.

[36] Ke X B, You K, Pichaud M, et al. Gut bacterial metabolites modulate endoplasmic reticulum stress[J]. Genome Biol, 2021, 22(1):292.

[37] Sun S Q, Yang S, An N N, et al. Astragalus polysaccharides inhibits cardiomyocyte apoptosis during diabetic cardiomyopathy via the endoplasmic reticulum stress pathway[J]. J Ethnopharmacol, 2019, 238:111857.

[38] Li X Y, Shen L, Ji H F. Astragalus alters gut-microbiota composition in type 2 diabetes mice:Clues to its pharmacology[J]. Diabetes Metab Syndr Obes, 2019, 12:771-778.

[39] Wang J Y, Chen P W, Cao Q Y, et al. Traditional Chinese medicine ginseng Dingzhi Decoction ameliorates myocardial fibrosis and high glucose-induced cardiomyocyte injury by regulating intestinal flora and mitochondrial dysfunction[J]. Oxid Med Cell Longev, 2022, 2022:9205908.

[40] Wang X, Chen X X, Zhou W Q, et al. Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways[J]. Acta Pharm Sin B, 2022, 12(2):708-722.

[41] Shi J, Zhao Q, Hao D D, et al. Gut microbiota profiling revealed the regulating effects of salidroside on iron metabolism in diabetic mice[J]. Front Endocrinol, 2022, 13:1014577.

[42] Yang J J, Song J Y, Zhou J D, et al. Functional components of Chinese rice wine can ameliorate diabetic cardiomyopathy through the modulation of autophagy, apoptosis, gut microbiota, and metabolites[J]. Front Cardiovasc Med, 2022, 9:940663.

[43] Li Z H, Wu Z Y, Yan J Y, et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis[J]. Lab Invest, 2019, 99(3):346-357.

[44] 杨天舒.鹿芪颗粒改善肠道菌群及其代谢产物TMAO延缓心室重构的机制研究[D].上海:上海中医药大学, 2020.

[45] 程安然,王钰滢,华健,等.黄芪-葛根药对治疗糖尿病心肌病的理论探讨[J].中草药, 2023, 54(23):7853-7861.

[46] 孟祥慧,张伯礼,李玉红,等.中药基于Nrf2/ARE通路改善糖尿病心肌病的研究进展[J].中草药, 2022, 53(1):250-260.

[47] 陆高辰,张发明.肠道菌群重建的层次及其核心介入途径[J].中国科学:生命科学, 2023, 53(5):582-593.